A Two-Cytokine Module Reconstructs Acinetobacter baumannii–Driven Immunopathology and Reveals IRF1 as a Targetable Node

When the body fights a severe bacterial infection, it often launches a massive defense that can turn against itself. This is the essence of sepsis, a condition where the immune system's response becomes so chaotic that it damages the very organs it is trying to protect. In this state, the body releases a flood of chemical signals called cytokines, which are meant to rally the immune cells to the site of infection. However, when these signals are released in the wrong combinations or at the wrong intensity, they can trigger a catastrophic chain reaction. Instead of simply killing the bacteria, the immune system begins to destroy the host's own tissues, leading to organ failure and often death. For decades, scientists have known that this "cytokine storm" is a major killer, but the specific recipe of chemical signals that drives this self-destruction has remained a mystery.

A team of researchers at The Hong Kong Polytechnic University and other institutions has now identified a precise two-part combination of these chemical signals that acts as the primary trigger for this lethal process in infections caused by Acinetobacter baumannii. This bacterium is a dangerous pathogen known for causing hospital-acquired infections that are difficult to treat with standard antibiotics. The researchers discovered that while individual chemical signals from the immune system are not enough to kill the body's own defense cells, a specific pairing of two signals—Interleukin-1 and Interferon-gamma—works together to destroy them. This finding shifts the focus from trying to suppress the entire immune system to blocking just this specific partnership, offering a new way to stop the damage without leaving the patient defenseless against the bacteria.

The journey to this discovery began with a look at the lungs of mice infected with Acinetobacter baumannii. The researchers analyzed the genetic activity in these lungs and found that thirteen different inflammatory genes were turned on. They also measured the levels of these signals in the blood and saw that several were present in high amounts. To understand which of these signals were actually dangerous, the scientists took immune cells from mice and human cell lines and exposed them to these chemicals. When they added just one type of signal at a time, the cells remained healthy. Even when they added all thirteen signals together, the cells died, but the researchers needed to know which specific pair was responsible. They systematically tested every possible combination of two signals. Only one pairing stood out: when Interleukin-1 (specifically the alpha or beta versions) was combined with Interferon-gamma, the immune cells died rapidly and in large numbers. Neither signal alone could cause this damage; it required both to be present simultaneously to cross a threshold of destruction.

To see if this deadly partnership worked in a living animal, the researchers injected mice with these two signals together. The result was immediate and severe. Within eighteen hours, every mouse that received the combination of Interleukin-1 and Interferon-gamma had died. The animals suffered from widespread tissue damage, including severe injury to the gut and liver, mirroring the multi-organ failure seen in human sepsis. The researchers observed that the immune cells in the lungs and spleen were dying in a coordinated fashion, a process that involves the simultaneous activation of three different cell-death pathways. This specific type of cell death, which the researchers refer to as a unified inflammatory death program, causes the cells to burst and release their contents, further fueling the inflammation and damaging surrounding tissues.

The study then moved to see if stopping this specific chemical partnership could save lives. The researchers treated mice that had been infected with the bacteria, or that had been injected with the deadly cytokine pair, with antibodies designed to neutralize these two signals. In the mice that received the antibodies, the death rate dropped dramatically. Those that were infected with the bacteria and treated with the neutralizing antibodies saw their survival rate rise from zero to eighty percent. Furthermore, these treated mice had significantly lower amounts of bacteria in their organs, suggesting that by stopping the self-inflicted damage, the body's own immune system was better able to clear the infection. This proved that the lethal outcome was not just a result of the bacteria multiplying, but largely due to the host's own overreaction to a specific two-signal combination.

Digging deeper, the researchers wanted to find the master switch inside the cells that allowed these two signals to cause such devastation. They compared the genetic activity of cells exposed to the deadly cytokine pair with cells infected by the bacteria and found a common regulator: a protein called IRF1. This protein acts as a central hub that integrates the instructions from both signals. When the researchers used a drug to block IRF1, the immune cells survived the attack, and the mice treated with this drug were protected from death, even when infected with the bacteria. The drug reduced the tissue damage and lowered the bacterial load, showing that IRF1 is a critical node where the path to fatal inflammation begins. Interestingly, blocking a different protein that was also active in the system did not offer the same protection, highlighting that IRF1 is the specific target needed to break the cycle of death.

The implications of these findings are significant for how we might treat severe infections in the future. The research suggests that the key to surviving sepsis caused by Acinetobacter baumannii may not be to kill the bacteria faster, but to stop the body from destroying itself in the process. By identifying that a simple two-signal combination drives the lethal inflammation, and that a single protein, IRF1, controls the execution of this plan, the study points to a new strategy for therapy. Instead of broad, blunt suppression of the immune system, which can leave patients vulnerable to other infections, doctors could potentially use targeted treatments to block this specific pathway. This approach would allow the immune system to continue fighting the bacteria while preventing the catastrophic self-destruction that currently kills so many patients. The researchers validated these findings using not only a standard laboratory strain of the bacteria but also real-world clinical isolates, suggesting that this mechanism is a fundamental part of how this dangerous pathogen causes disease in humans.